Target Name: ETS1
NCBI ID: G2113
Review Report on ETS1 Target / Biomarker Content of Review Report on ETS1 Target / Biomarker
ETS1
Other Name(s): EWSR2 | v-ets avian erythroblastosis virus E26 oncogene homolog 1 | c-ets-1 | Avian erythroblastosis virus E26 (v-ets) oncogene homolog-1 | ETS1_HUMAN | v-ets Erythroblastosis virus E26 oncogene homolog 1 | ETS proto-oncogene 1, transcription factor, transcript variant 2 | ETS1 variant 2 | p54 | Protein C-ets-1 (isoform 2) | Protein C-ets-1 | Protein C-ets-1 (isoform 1) | ETS1 variant 1 | Protein C-ets-1 (isoform 3) | ETS1 transcription factor | V-ets avian erythroblastosis virus E2 oncogene homolog 1 | v-ets avian erythroblastosis virus E2 oncogene homolog 1 | ETS-1 | ETS proto-oncogene 1, transcription factor, transcript variant 1 | ETS proto-oncogene 1, transcription factor | ETS proto-oncogene 1, transcription factor, transcript variant 3 | ETS1 variant 4 | p541 | ETS proto-oncogene 1, transcription factor, transcript variant 4 | Protein C-ets-1 (isoform 4) | ETS1 variant 3

ETS1: A Potential Drug Target for Sleep Disorders and Neurological Disorders

ETS1 (Early-Upon-Sleeping gene 1), also known as EWSR2, is a gene that has been identified as a potential drug target for the treatment of various sleep disorders, including insomnia, depression, and sleep apnea. ETS1 is a non-coding RNA molecule that has been shown to play a role in regulating sleep-wake cycles and has been linked to the control of various sleep-related behaviors.

In addition to its role in sleep regulation, ETS1 has also been shown to play a key role in the development and progression of certain neurological disorders, including Alzheimer's disease and Parkinson's disease. This has led to the speculation that ETS1 may be a valuable drug target for the treatment of these disorders.

The ETS1 gene has been shown to be involved in the regulation of several key genes that are involved in the development and progression of these disorders. For example, studies have shown that ETS1 can interact with the gene for the protein serotonin, which is involved in mood regulation. Additionally, ETS1 has been shown to be involved in the regulation of the gene for the protein dopamine, which is involved in the pleasure and reward aspects of drug use.

In addition to its role in the regulation of sleep and the development of neurological disorders, ETS1 has also been shown to play a role in the regulation of inflammation. This has led to the hypothesis that ETS1 may be a valuable drug target for the treatment of chronic inflammatory disorders, such as rheumatoid arthritis and inflammatory bowel disease.

Overall, the potential drug targets for ETS1 are vast and continue to be explored by researchers. While further studies are needed to fully understand the role of ETS1 in the treatment of sleep disorders and other neurological disorders, the potential for ETS1 as a drug target is a promising area of research that may lead to new and effective treatments for these disorders.

Protein Name: ETS Proto-oncogene 1, Transcription Factor

Functions: Transcription factor (PubMed:10698492, PubMed:11909962). Directly controls the expression of cytokine and chemokine genes in a wide variety of different cellular contexts (PubMed:20378371). May control the differentiation, survival and proliferation of lymphoid cells (PubMed:20378371). May also regulate angiogenesis through regulation of expression of genes controlling endothelial cell migration and invasion (PubMed:15247905, PubMed:15592518)

The "ETS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ETS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ETS2 | ETS2-AS1 | ETV1 | ETV2 | ETV3 | ETV3L | ETV4 | ETV5 | ETV6 | ETV7 | Eukaryotic translation initiation factor 2-alpha kinase | Eukaryotic translation initiation factor 2B | Eukaryotic translation initiation factor 3 (eIF-3) complex | Eukaryotic Translation Initiation Factor 4A (eIF-4A) | Eukaryotic Translation Initiation Factor 4E Binding Protein | EVA1A | EVA1A-AS | EVA1B | EVA1C | EVC | EVC2 | EVI2A | EVI2B | EVI5 | EVI5L | EVL | EVPL | EVPLL | EVX1 | EVX1-AS | EVX2 | EWSAT1 | EWSR1 | EXD1 | EXD2 | EXD3 | EXO1 | EXO5 | EXOC1 | EXOC1L | EXOC2 | EXOC3 | EXOC3-AS1 | EXOC3L1 | EXOC3L2 | EXOC3L4 | EXOC4 | EXOC5 | EXOC5P1 | EXOC6 | EXOC6B | EXOC7 | EXOC8 | Exocyst complex | EXOG | EXOGP1 | Exon junction complex | EXOSC1 | EXOSC10 | EXOSC10-AS1 | EXOSC2 | EXOSC3 | EXOSC4 | EXOSC5 | EXOSC6 | EXOSC7 | EXOSC8 | EXOSC9 | Exosome Complex | EXPH5 | EXT1 | EXT2 | EXTL1 | EXTL2 | EXTL2P1 | EXTL3 | EXTL3-AS1 | EYA1 | EYA2 | EYA3 | EYA4 | EYS | EZH1 | EZH2 | EZHIP | EZR | F10 | F11 | F11-AS1 | F11R | F12 | F13A1 | F13B | F2 | F2R | F2RL1 | F2RL2 | F2RL3 | F3 | F5